Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 4
2021 5
2022 6
2023 8
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Comparing different robots available in the European market for the preparation of injectable chemotherapy and recommendations to users.
Cerutti A, Ledoux T, Vantard N, Cerfon MA, Kimbidima R, Larbre V, Herledan C, Lattard C, Baudouin A, Caffin AG, Schwiertz V, Ranchon F, Rioufol C. Cerutti A, et al. Among authors: herledan c. J Oncol Pharm Pract. 2023 Oct;29(7):1599-1612. doi: 10.1177/10781552221143786. Epub 2022 Dec 14. J Oncol Pharm Pract. 2023. PMID: 36999226 Review.
Thromboembolic events and thromboprophylaxis associated with immunomodulators in multiple myeloma patients: a real-life study.
Leclerc V, Karlin L, Herledan C, Marchal L, Baudouin A, Gouraud A, Caffin AG, Larbre V, Lazareth A, Bachy E, Salles G, Ghesquières H, Rioufol C, Ranchon F. Leclerc V, et al. Among authors: herledan c. J Cancer Res Clin Oncol. 2022 Apr;148(4):975-984. doi: 10.1007/s00432-021-03693-5. Epub 2021 Jun 18. J Cancer Res Clin Oncol. 2022. PMID: 34143239
Preparations of exploration of immediate hypersensitivity to antineoplastic agents: An oncology pharmacy perspective.
Dubromel A, Caffin AG, Hacard F, Vantard N, Baudouin A, Herledan C, Larbre V, Schwiertz V, Nosbaum A, Pralong P, Nicolas JF, Berard F, Rioufol C, Ranchon F. Dubromel A, et al. Among authors: herledan c. J Oncol Pharm Pract. 2022 Oct;28(7):1552-1559. doi: 10.1177/10781552211035695. Epub 2021 Sep 21. J Oncol Pharm Pract. 2022. PMID: 34546819
Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program.
Collomb B, Dubromel A, Caffin AG, Herledan C, Larbre V, Baudouin A, Cerutti A, Couturier L, Maire M, Karlin L, Maucort-Boulch D, Huot L, Dalle S, Bachy E, Ghesquieres H, Salles G, Couraud S, You B, Freyer G, Trillet-Lenoir V, Ranchon F, Rioufol C. Collomb B, et al. Among authors: herledan c. Cancers (Basel). 2022 Jan 28;14(3):660. doi: 10.3390/cancers14030660. Cancers (Basel). 2022. PMID: 35158928 Free PMC article.
20 results